VASH2 and neoplasm: Importantly, EpoY reduced VASH2 secretion into the supernatants in a dose-dependent manner (Fig. S7), suggesting that TCP inhibitor may inhibit the pro-angiogenic effects of VASH2 in the tumor microenvironment by reducing the secretion of soluble VASH2 in LUSC cells.